In the context of viral infections, in vitro studies have indicated that treatment with a SIRT1 antagonist (EX-527) generates an increase in the production of influenza viruses and human cytomegalovirus (HCMV) infection, while SIRT1 agonists promote a reduction in the production of viral particles (204). Here, SIRT1 is linked to viral infectious disease.